Company News

Hair Regeneration Company Closes $15 Million Series A

Stemson Therapeutics’ novel cell regeneration technology uses patient’s own cells to generate new hair follicles.

Author Image

By: Christine Esposito

Editor-in-Chief

Stemson Therapeutics has closed a DCVC Bio-led $15 million Series A financing to advance development of its proprietary therapeutic solution for hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting the San Diego-based company's efforts to restore human hair growth with a novel cell regeneration technology using the patient’s own cells to generate new hair follicles. The AbbVie Venture investment follows an initial seed investment from Allergan Aesthetics in 2...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters